GVHO-Pathway (Netherlands) in United Arab Emirates

How the gvho-pathway (netherlands) pathway operates in United Arab Emirates.

About GVHO-Pathway (Netherlands)

Netherlands' pathway for group or individual compassionate access.

How GVHO-Pathway (Netherlands) works in United Arab Emirates

The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.

Patients in United Arab Emirates seeking access under GVHO-Pathway (Netherlands) typically follow this flow: a licensed physician in United Arab Emirates issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in United Arab Emirates

  • Physician prescription and clinical-justification letter.
  • Patient identification and consent.
  • Country-specific NPP/personal-import form.
  • Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 1 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under GVHO-Pathway (Netherlands) in United Arab Emirates

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (sourced through Altima Care, a US-licensed specialty wholesaler) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp